Nektar Threraputics (NKTR) to Report Phase 2a Clinical Results Regarding the use of NKTR-061 to Treat Gram-Negative Hospital-Acquired Pneumonia
More News related to NKTR
- Brean Murray Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Expect Substantial Value Creation Through Partnerships
- Morning Movers 6/19: ZZ, OCLS, SWHC, GLUU, NKTR Higher; TSFG, ETFC, TNK, SSL Lower
- Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR); Partner Momentum Building
- Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
- Unusual 11 Mid-Day Movers 5/14: CAEI, GIL, NKTR, FBC Higher; GIL, BEXP, ACMR, GASS, ENS Lower
More News related to FDA
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
- Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
Nektar Therapeutics (Nasdaq: NKTR) says results of a Phase 2a clinical trial evaluating the use of NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated patients with hospital-acquired gram-negative pneumonia were presented today during a poster session from 11:15 a.m. - 2:00 p.m. Eastern Time at the annual American Thoracic Society (ATS) International Conference.
NKTR-061 (inhaled amikacin) is currently being tested to further evaluate the safety, tolerability, and deep lung concentrations of amikacin formulated for inhalation for the adjunctive treatment of gram-negative pneumonia in ventilated patients diagnosed with hospital or ventilator associated pneumonia.
Four poster-board abstracts will illuminate the results of the Phase 2a trial, which allowed the evaluation of NKTR-061's pharmacokinetic, serum and tracheal aspirate concentrations, and its safety and antibiotic reduction properties. The four abstracts are available on the Investor Relations section of the Nektar Therapeutics website: www.nektar.com.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
